GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PRAXIS PRECISION MEDICINES INC

Financial Performance:

• The company holds approximately $1.3 billion in cash reserves, providing an extended runway into 2028.
• This capital base is sufficient to cover upcoming launch costs for Ulexa and Retrogene while continuing pipeline advancement.
• No specific revenue, earnings, or margin figures were disclosed during this call, as the focus remains on regulatory milestones and pre-revenue stages.

Guidance and Future Outlook:

• Ulexacalpidime (Elixir): Strong confidence in FDA approval by the PDUFA deadline in January; immediate launch execution is planned upon receipt of the approval letter.
• Retrogene (Retrogene): A PDUFA date is expected shortly after December 27; the review is slightly behind Ulexa's timeline due to information requests but no critical IRs remain.
• Emerald (DRE/SCN2A/SCN8A): Data readout expected later this week with a potential NDA submission for the DRE indication contingent on data; BRAVE3 study is sufficient for the NDA submission for the epilepsy indication.
• Rometrogene: Power 2 study is active; Power 3 study is expected to commence next year.
• Investor Day: A comprehensive update is scheduled for Thursday, featuring data on Emerald, pricing analysis, and NDA submission timelines.

Business Segments and Product Lines:

• Ulexacalpidime: Under review for Essential Tremor; late-cycle meeting concluded with FDA focusing on labeling, specifically titration schedules to manage high discontinuation rates. The drug is being proposed with no scheduling (non-controlled substance), though a Schedule V classification is considered a remote possibility.
• Retrogene: NDA for Dravet Syndrome review is advanced; the company anticipates a broad label with no negative subgroup impacts. Post-approval studies (if any) are expected to have minimal impact.
• Emerald: Enrolling in a study for SCN2A and SCN8A disorders (DRE); study design includes rigorous data quality control. The addressable patient market is estimated at 30 times larger than the current rare disease cohort (approx. 5,000–10,000 vs. 300,000+ for DE).
• Rometrogene: Early-stage development with Power 2 ongoing and Power 3 planning for next year.

Market and Competitive Landscape:

• Ulexa: Positioned to treat Essential Tremor; FDA agreed with the assessment that no specific patient subgroup shows reduced efficacy.
• Emerald/DRE: Targeting a large, unmet need in DRE (approx. 200,000–400,000 patients in the US); management expects significant revenue potential per market share point gained.
• Competition: Management noted that other drugs are launching without price hikes, positioning their upcoming data and pricing strategy as competitive differentiators.
• Market Size: Emphasis on the vast potential in the DRE market compared to the smaller SCN2A/8A populations.

Risks and Challenges:

• Scheduling Uncertainty: Potential for Ulexa to be classified as Schedule IV or V, which could complicate the supply chain, though management believes launch performance will not be impacted.
• Labeling: The final label text regarding titration and discontinuation is not yet finalized, which could influence physician adoption and ramp speed.
• Data Timing: The Emerald data release timing was intentionally kept vague in the press release to account for administrative delays (form signing/QC) rather than clinical issues.
• Regulatory Process: Retrogene has slightly more uncertainty than Ulexa due to recent information requests, though no deal-breakers have been identified.

Management Commentary and Tone:

• Confidence: Tone was highly optimistic and confident, particularly regarding Ulexa's FDA relationship, which management described as "very aligned" and "happy."
• Strategic Clarity: Management emphasized a shift from opinion-based to data-based arguments, particularly regarding pricing and market potential for the DRE indication.
• Communication Style: CEO Marcio Marquez and CFO Tim Kelly provided detailed, transparent updates, openly addressing minor delays in the Retrogene review and study logistics without signaling distress.
• Forward-Looking: Management indicated that the upcoming Investor Day will resolve open questions regarding pricing and data cross-tribe comparisons.

Analyst Questions and Answers:

• Launch Speed: Confirmed that Ulexa can launch immediately upon approval; scheduling status is the only variable for shipping readiness.
• Label Impact: Label discussions focused on titration; management expects no negative impact on efficacy or broad patient inclusion.
• Emerald Data: Clarified that the study is enantiomer-driven (genetics-based), with very low representation of SCN1A patients to avoid historical concerns.
• Pricing: Reiterated that pricing will be justified by data during the Thursday presentation, dismissing debates on price increases as "stupid" given the unmet need.
• Financial Health: CFO confirmed the $1.3B cash balance covers all near-term activities through 2028.

Other Key Points:

• Data Quality: The Emerald study employs a "QC every entry" approach, which delays the announcement slightly but ensures high-quality data for the FDA and market.
• Investor Day: Scheduled for Thursday, featuring a full summation of Retrogene and Ulexa updates, Emerald data, and strategic financial guidance.
• Patient Needs: Repeated emphasis on the humanitarian and medical benefits of the pipeline, specifically for fragile patient populations in DRE and Essential Tremor.
• Regulatory Personnel: Acknowledged that changes in FDA review team members (recent retirements) may have contributed to the slight pace difference in the Retrogene review.